Welcome to our dedicated page for Lucid Diagnostics SEC filings (Ticker: LUCD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Lucid Diagnostics Inc. filings document a commercial-stage medical diagnostics issuer focused on esophageal precancer detection, its public-company governance, and its capital structure. Its 8-K reports disclose operating results and business updates for EsoGuard and EsoCheck, Regulation FD communications, completed common stock offerings, shelf registration statement references, proceeds for working capital and general corporate purposes, and related exhibits.
Proxy materials cover annual meeting matters, director elections, board classification, and stockholder voting. Other material-event filings address board appointments, non-employee director compensation arrangements, indemnification agreements, and governance rights associated with holders of the company’s convertible secured promissory notes due 2029.
Lucid Diagnostics (LUCD) is a commercial-stage cancer-prevention diagnostics company selling the EsoGuard test with EsoCheck sampling. For the three and six months ended June 30, 2025 the company recognized $1.16 million and $1.99 million of revenue, respectively, while reporting a net loss attributable to common stockholders of $7.9 million for the quarter and $43.9 million for the six months. Operating activities used $23.0 million of cash in the first half of 2025, leaving $31.1 million of cash and approximately $4.4 million of working capital as of June 30, 2025.
Key balance sheet and financing items include total assets of $38.7 million, stockholders' equity of $7.9 million, and Senior Secured Convertible Notes with $21.975 million face value carried at fair value of $25.3 million (conversion price $1.00; 12% stated interest). Management discloses substantial doubt about going concern absent increased reimbursement, revenue growth or additional financing. Recent developments include two equity raises in March and April 2025 netting ~$31.0 million, an ATM up to $25.0 million, Highmark coverage in New York effective May 26, 2025, MolDx LCD reconsideration (CAC on Sept 4, 2025), multiple peer-reviewed publications, and an $8.0 million NIH R01 award to CWRU investigators.